Timing Is Everything: 4 Trends to Bolster Your HCP Marketing Strategy
In the past few years, it’s become more challenging for pharmaceutical companies to promote their products directly to healthcare providers (HCPs), and COVID only exacerbated this trend. Physicians are more selective in who they choose to meet with, and many no longer accept face-to-face meetings with pharmaceutical reps. According to 2023 research, more than 50% […]
Uncovering the Patient Journey: Four Ways that Real-World Data Offers Value
This article was originally published in STAT. For manufacturers, building a static commercialization strategy will only take you so far. But infusing that strategy with real-world data (RWD) — consisting of medical claims, lab testing and pharmacy data, and electronic health records — provides a more holistic view of the patient journey. RWD fills in crucial missing […]
How to Leverage Real-World Data in Your Commercial Strategy
In the past few years, real-world data (RWD) has become an increasingly important element of a successful market access strategy. By blending claims and lab data with clinical pathway and payer coverage data, pharma companies can get full visibility into what’s happening in the market. But how, exactly? What can a unified source of RWD […]
Driving Market Access for Rare Disease Therapies
In the past, rare disease manufacturers often assumed that any therapy they launched would automatically be covered by most health plans. But the rising cost of many rare disease drugs has increased payer sensitivity to the expense of these therapies, even those with orphan drug designation. Many rare disease treatments are placed in the highest […]
How Real-World Data Helps Manufacturers See the Complete Market Access Story
This article was originally published in BioPharma Dive. Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning. Manufacturers typically track formulary and medical policy guidelines and restrictions—including prior authorization and step therapy requirements—for a product and its competitors, […]
Is Lab Data the Secret Weapon for More Efficient Clinical Trials?
According to the National Institutes of Health (NIH), approximately 80% of research studies fail to meet their enrollment goals within the stated timeframes. Recruitment and trial design challenges can prolong the timeline for phase III studies, driving up costs and delaying market entry. While many sponsors use aggregated data and predictive analytics to improve the […]
Integrating Lab Data Into Your Physician Engagement Strategy: 5 Key Benefits
This article was originally published in BioPharma Dive. In the competitive pharma marketplace, physician engagement plays a critical role in a drug manufacturer’s commercialization strategy. However, before manufacturers can promote a new therapy directly to providers, they must first determine which physicians treat the relevant patient population. By investing in timely lab data, manufacturers can […]